<?xml version="1.0" encoding="UTF-8"?>
<p class="p">In patients older than 55 years, age-related macular degeneration (AMD) is considered the leading cause of serious visual loss in the developed world [
 <xref rid="B97-marinedrugs-17-00374" ref-type="bibr" class="xref">97</xref>,
 <xref rid="B181-marinedrugs-17-00374" ref-type="bibr" class="xref">181</xref>], and the third leading cause of blindness in the world [
 <xref rid="B182-marinedrugs-17-00374" ref-type="bibr" class="xref">182</xref>]. AMD is a degenerative disease caused by the concomitant presence of non-modifiable (genetics, sex, age) and modifiable factors (nutritional status, smoking status) (
 <xref ref-type="fig" rid="marinedrugs-17-00374-f005" class="xref">Figure 5</xref>) [
 <xref rid="B183-marinedrugs-17-00374" ref-type="bibr" class="xref">183</xref>]. Several genetic associations have been found, the most studied are those related to inflammatory genes such as complement factor H and certain complement components (i.e., C3 and C2) [
 <xref rid="B184-marinedrugs-17-00374" ref-type="bibr" class="xref">184</xref>]. Recently, a tissue-adaptive response, called para-inflammation, where the innate immune system engages a low-grade inflammatory response to restore tissue homeostasis, has been associated to the pathogenesis of ADM [
 <xref rid="B185-marinedrugs-17-00374" ref-type="bibr" class="xref">185</xref>].
</p>
